Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 8

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 8
---
 be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier.
Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment
technology.

In addition to the foregoing, we are monitoring closely
the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and the surrounding
areas, as well as related political and economic responses and counter-responses by various global factors on our business. Given the
level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess
the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing military
conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will depend on
future developments, as well as the economic impact on national and international markets that are highly uncertain.

We incorporated in Nevada on March 10, 1999. Our executive
offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our
website address is www.aethlonmedical.com.

Our common stock is listed on the Nasdaq Capital Market under the symbol
“AEMD.”

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

During the three months ended June 30, 2025, there
were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March
31, 2025.

REVERSE STOCK SPLIT

On June 9, 2025, we effected a 1-for-8 reverse stock
split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our stockholders
were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole
share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated
financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred
on April